NeuroNews issue 49 – EU



  • The 2023 International Stroke Conference (ISC; 8–10 February, Dallas, USA) is punctuated by new data on neuroprotective medications in ischaemic stroke, sparking tempered optimism from delegates
  • Other late-breaking highlights from ISC 2023 include findings on tenecteplase’s utility versus alteplase as an intravenous thrombolytic; bypass surgery in symptomatic arterial occlusion patients; and thrombectomy’s benefits over standard care in large infarct-core volume strokes
  • A European Stroke Organisation (ESO) taskforce delivers an update—and a recap—
    on recent shortages of intravenous thrombolysis drugs in European stroke care
  • PROFILE: Vitor Mendes Pereira (Toronto, Canada), a pioneer in neuroendovascular robotics, discusses his achievements to date, offers advice to budding neurointerventionists, and speculates on the future of the specialty
  • NEUROMODULATION: The European Society for Brain Stimulation (ESBS) challenges the European Union’s (EU) recent decision to reclassify non-invasive brain stimulation technologies as Class III medical devices, describing it as a “sudden and unwelcome” regulatory change


Please enter your comment!
Please enter your name here